192 related articles for article (PubMed ID: 3145996)
1. [Improvement in anti-hemophilic preparations and its problems. 4. Factor VIII preparation (RCG-5) with intermediate purity and potency].
Yoshioka A
Rinsho Ketsueki; 1988 May; 29(5):649-54. PubMed ID: 3145996
[No Abstract] [Full Text] [Related]
2. [Improvement in anti-hemophilic preparations and arts problems. 1. Heat-treated concentrates].
Ikematsu S; Yorifuji H; Arai M; Fukutake K
Rinsho Ketsueki; 1988 May; 29(5):628-34. PubMed ID: 3145993
[No Abstract] [Full Text] [Related]
3. Human factor VIII:C purified using monoclonal antibody to von Willebrand factor.
Levine PH
Semin Hematol; 1988 Apr; 25(2 Suppl 1):1-2. PubMed ID: 3133770
[No Abstract] [Full Text] [Related]
4. [New prospects in the treatment of hemophilia. High-purity concentrates of factor VIII].
Tusell Puigbert JM
Med Clin (Barc); 1993 May; 100(17):655-8. PubMed ID: 8497171
[No Abstract] [Full Text] [Related]
5. Factor VIII concentrate: what is "high purity"?
Schoppmann A; Weber A; Hondl F; Linnau Y
Thromb Haemost; 1994 Sep; 72(3):483-4. PubMed ID: 7855803
[No Abstract] [Full Text] [Related]
6. [Transmission of the human immunodeficiency virus by a dry heat-treated Factor VIII concentrate?].
Weisser J
Klin Padiatr; 1988; 200(5):375-9. PubMed ID: 3141670
[TBL] [Abstract][Full Text] [Related]
7. [Improvement in anti-hemophilic preparations and its problems. 7. Present status and future aspect of anti-hemophilic preparations].
Kamiya T
Rinsho Ketsueki; 1988 May; 29(5):666-70. PubMed ID: 3145998
[No Abstract] [Full Text] [Related]
8. Survey of non-U.S. hemophilia treatment centers for HIV seroconversions following therapy with heat-treated factor concentrates.
Centers for Disease Control (CDC)
MMWR Morb Mortal Wkly Rep; 1987 Mar; 36(9):121-4. PubMed ID: 3102937
[No Abstract] [Full Text] [Related]
9. Factor VIII fractionation on aminohexyl Sepharose with possible reduction in hepatitis B antigen.
Austen DE; Smith JK
Thromb Haemost; 1982 Aug; 48(1):46-8. PubMed ID: 6813994
[TBL] [Abstract][Full Text] [Related]
10. Changes in factor VIII complex activities during the production of a clinical intermediate purity factor VIII concentrate.
Prowse CV; Griffin B; Pepper DS; Dickson AJ; McQuillan TA; Dickson IH; Foster PR
Thromb Haemost; 1981 Oct; 46(3):597-601. PubMed ID: 6797090
[TBL] [Abstract][Full Text] [Related]
11. Progress and problems in hemophilia and von Willebrand's disease.
Abildgaard CF
Adv Pediatr; 1984; 31():137-77. PubMed ID: 6440429
[No Abstract] [Full Text] [Related]
12. [Cryoprecipitate should have preference over factor VIII concentrate in the treatment of patients with hemophilia A].
Kunst VA; Nováková IR; Haanen C
Ned Tijdschr Geneeskd; 1989 Jun; 133(23):1163-6. PubMed ID: 2501689
[No Abstract] [Full Text] [Related]
13. Factor VIII/von Willebrand factor.
Zimmerman TS; Ruggeri ZM; Fulcher CA
Prog Hematol; 1983; 13():279-309. PubMed ID: 6422506
[No Abstract] [Full Text] [Related]
14. [Plasma concentrates of factor VIII. Where are we?].
Vicente V
Sangre (Barc); 1989 Feb; 34(1):1-3. PubMed ID: 2496481
[No Abstract] [Full Text] [Related]
15. [Factor VIII concentrates].
Faber JC
Bull Soc Sci Med Grand Duche Luxemb; 1986; 123(2):27-9. PubMed ID: 3100076
[No Abstract] [Full Text] [Related]
16. High purity factor VIII and immune state in HIV.
Nurs Stand; 1993 Oct 6-12; 8(3):17. PubMed ID: 8217692
[No Abstract] [Full Text] [Related]
17. von Willebrand factor contained in factor VIII concentrates of different purities supports platelet adhesion in blood samples from a heterogeneous group of patients with von Willebrand disease.
Escolar G; Carretero M; Magallón M; Quintana M; Arnau C; Castillo R; Aznar-Salatti J
Haematologica; 1998 Nov; 83(11):1009-14. PubMed ID: 9864923
[TBL] [Abstract][Full Text] [Related]
18. [Anti-hemophilia drugs: from cryoprecipitate to factor VIII concentrates of high purity].
Gutsalo AE; Varetskaia TV; Kozulina EP; Papaian LP
Ukr Biokhim Zh (1978); 1995; 67(1):3-13. PubMed ID: 8588250
[TBL] [Abstract][Full Text] [Related]
19. Development and present status of concentrate therapy for hemophilia and von Willebrand's disease.
Brinkhous KM
Wien Klin Wochenschr; 1982 Oct; 94(19):509-14. PubMed ID: 6818773
[TBL] [Abstract][Full Text] [Related]
20. [Hemostatic effect of deamino-8-D-arginine vasopressin (DDAVP) in hemophilia A and von Willebrand's disease].
Fukui H; Takase T
Rinsho Ketsueki; 1985 Jul; 26(7):1069-79. PubMed ID: 3932720
[No Abstract] [Full Text] [Related]
[Next] [New Search]
